Skip to main content

Home/ Health affairs/ Group items tagged Arrowhead-HSD

Rss Feed Group items tagged

pharmacybiz

GSK And Arrowhead To Develop drug For Fatty Liver Disease - 0 views

  •  
    Arrowhead Pharmaceuticals on Monday (November 22) entered a drug development deal with GlaxoSmithKline (GSK) under which the British drugmaker will develop and market Arrowhead's potential treatment for patients with fatty liver disease NASH. Under the pact, Arrowhead said it would get an upfront payment of $120 million and is eligible for additional milestone payments including up to $190 million at first commercial sale of the product, and up to $590 million in sales-related milestone payments. The drug candidate, ARO-HSD, is currently in an early-to-mid stage trial for nonalcoholic steatohepatitis (NASH), a fatty liver disease. It is based on RNA interference technology, where genes that contribute to disease are silenced.
1 - 1 of 1
Showing 20 items per page